MichaelAndrewRogawskiMDPhD
Neurology • Sacramento, CADistinguished Professor, School of Medicine, University of California, Davis
Dr. Rogawski is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4860 Y St
Ste 3700
Sacramento, CA 95817Phone+1 916-734-6275Fax+1 916-724-6526
Education & Training
Johns Hopkins UniversityResidency, Neurology, 1984 - 1986
Clinical Center at the National Institutes of HealthResidency, Neurology, 1983 - 1984- Johns Hopkins UniversityResidency, Neurology, 1982 - 1983
- Clinical Center at the National Institutes of HealthResidency, Neurology, 1981 - 1982
Yale-New Haven Medical Center (Waterbury)Internship, Internal Medicine, 1980 - 1981
Yale School of MedicineClass of 1980
Certifications & Licensure
CA State Medical License 2007 - 2025
MD State Medical License 1982 - 2007
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2012
Clinical Trials
- Efficacy and Safety of the Use of Memantine for Preserving Cognition in Adult Patients With Epilepsy Start of enrollment: 2010 Jul 01
- Allopregnanolone for the Treatment of Traumatic Brain Injury Start of enrollment: 2013 Apr 01
Publications & Presentations
PubMed
- 91 citationsA model of the T-type calcium current and the low-threshold spike in thalamic neuronsXiao Jing Wang, John Rinzel, Michael A. Rogawski
Journal of Neurophysiology. 1991-09-01 - 210 citationsRevisiting AMPA Receptors as an Antiepileptic Drug TargetMichael A. Rogawski
Epilepsy Currents. 2011-03-01 - 262 citationsTherapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines.Michael A. Rogawski
Trends in Pharmacological Sciences. 1993-09-01
Lectures
- 15th Annual Meeting of American Society for Experimental NeuroTherapeutics: ASENT 2013American Society for Experimental NeuroTherapeutics(ASENT), Bethesda, Maryland - 2/28/2013
- Neurology Update 2012: Practical Information for the Primary Care ProviderUC Davis Health System, Sacramento, California - 5/19/2012
Press Mentions
Xenon Pharmaceuticals Announces Completion of Patient Randomization in XEN1101 Phase 2b “X-TOLE” Clinical Trial and Announces Upcoming Investor Webinar with Leading Epilepsy Key Opinion LeadersJuly 7th, 2021- Neurologist Michael Rogawski Named Fellow of National Academy of InventorsDecember 9th, 2020
- Celebrating 20 YearsOctober 28th, 2020
- Join now to see all
Grant Support
- Training In Neurotherapeutics Discovery And Development For Academic ScientistsNational Institute Of Neurological Disorders And Stroke2012
- Identification Of Novel Therapeutic Approaches For Tets And OP IntoxicationNational Institute Of Neurological Disorders And Stroke2010–2011
- Ion Channels In Epilepsy And As Targets For AntiepileptiNational Institute Of Neurological Disorders And Stroke2001–2006
- Evaluation Of Novel Epilepsy Treatment ApproachesNational Institute Of Neurological Disorders And Stroke1998–2006
- Epilepsy: Ion Channels As Antiepileptic TargetsNational Institute Of Neurological Disorders And Stroke2004
- Ion Channels In Epilepsy And Targets For AntiepilepticsNational Institute Of Neurological Disorders And Stroke2003
- Ion Channels In Epilepsy And As Targets For Antiepileptic DrugsNational Institute Of Neurological Disorders And Stroke1998–2000
- Preclinical Evaluation Of Novel Anticonvulsant DrugsNational Institute Of Neurological Disorders And Stroke1993–1997
- Pharmacological Studies Of Ion Channels In Cultured CellsNational Institute Of Neurological Disorders And Stroke1993–1997
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
